Revance Therapeutics (RVNC) Misses Q1 EPS by 9c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.94), $0.09 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c